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Abstract Isolated sulfite oxidase deficiency is a rare autosomal recessive inborn error of sulfur metabolism. Clinical features generally include devastating neurologic dysfunction,
ectopia lentis, and increased urinary excretion of sulfite, thiosulfate, and S-sulfocysteine.
Missed diagnosis is not unusual because of variability in the sensitivity of the urinary sulfite
and thiosulfate screening test. We present clinical, biochemical, and molecular data on two
unrelated patients with isolated sulfite oxidase deficiency. The two patients belong to an
Indigenous genetic isolate in Manitoba, Canada. Both patients (one male and one female,
both now deceased) developed neonatal seizures and demonstrated progressive neurodevelopmental delay. Based on increased urinary excretion of sulfite, thiosulfate, and S-sulfocysteine and normal serum uric acid levels, sulfite oxidase deficiency was suspected. Both
patients have a homozygous 4-bp deletion, 1347–1350delTTGT in the sulfite oxidase gene
(SUOX), predicting a premature termination of the sulfite oxidase protein leading to absence of the carboxy-terminal third portion of the protein. This domain contains most of
the contact sites essential for enzyme dimerization. This deletion mutation resulted in sulfite
oxidase deficiency with early-onset severe clinical phenotype.
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The clinical and biochemical data on the two patients are presented in Tables 1 and 2,
respectively.

TECHNICAL ANALYSIS
Genomic DNA was isolated from cultured fibroblasts and/or blood samples, and the gene
encoding SUOX was amplified by polymerase chain reaction (PCR) using standard conditions. PCR primers spanning the entire coding region (CCTCAAGGATCTGCATTCAGGCC
and AAGGGGTGGAGGTGGCTCCTTTCC) were included at a concentration of 1 µmolar,
and the reaction was cycled for 30 sec at 55°, for 5 min at 68°, and for 30 sec at 95° for a total
of 35 cycles. The entire reaction mixture was run on an agarose gel and the band at ∼2.4 kb,
corresponding to the sulfite oxidase gene with its single intron, was extracted from the gel
and sequenced in both the forward and reverse directions. Automated DNA sequencing was
performed at the Duke University Comprehensive Cancer Center facility using a
PerkinElmer/ABI 377 DNA Sequencer and Big Dye sequencing chemistry. Numbering of nucleotides is based on the cDNA sequence, with the A of the ATG initiator methionine codon
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Table 1. Clinical findings
Age at
presentation

Sex

1

First week

F

Intractable seizures, severe
developmental delay, spastic
quadriplegia

Not assessed

2

5d

M

Lethargy, hypotonia, severe
developmental delay,
intractable seizures

Not assessed

Patient

Lens
dislocation

Symptoms

Ethnic
background

Current
status

Negative

Indigenous

Deceased at
9 yr

Possible affected
older sibling based
on history

Indigenous

Deceased at
15 mo

Family history

denoted nucleotide +1. Numbering of the amino acids is also from the initiator methionine,
which is the first amino acid in the 22-residue leader sequence of sulfite oxidase.

VARIANT INTERPRETATION
Both patients have a homozygous 4-bp deletion, 1347–1350delTTGT in the sulfite oxidase
gene (SUOX), predicting a premature termination of the sulfite oxidase protein leading to
absence of the carboxy-terminal third portion of the protein. This domain contains most
of the contact sites essential for enzyme dimerization. The parents are heterozygous for
this variant. This novel variant in SUOX likely is a founder mutation, given its presence in
two unrelated Indigenous children from the same genetic isolate (Table 3).
Isolated sulfite oxidase deficiency (MIM 272300) is an autosomal recessive disorder
caused by mutations in the sulfite oxidase gene (SUOX), GenBank accession number
AY056018. The gene is located on Chromosome 12, in the region of 12q13.2, and the coding sequence contains a single intron. The gene product, sulfite oxidase, is a molybdohemoprotein comprised of 466 amino acids. It is synthesized with a 22-residue leader sequence
that directs it to the mitochondrial intermembrane space. The mature protein lacks this presequence. The native enzyme is a dimer of identical subunits, each of which contains three
domains—the amino-terminal heme domain, the central molybdenum domain, and a carboxy-terminal domain with key residues at the dimer interface (Johnson and Rajagopalan
1976; Kisker et al. 1997). The enzyme catalyzes the oxidation of sulfite to sulfate, the terminal
reaction in the degradation of sulfur-containing amino acids, and transfers the electrons derived from substrate oxidation to cytochrome c on the inner mitochondrial membrane.
Sulfite oxidase deficiency is classically characterized by severe neurological symptoms
including seizures, often refractory to anticonvulsant medications, and rapidly progressing

Table 2. Biochemical findings
Analyte
(normal
range)

Urine S-sulfocysteine (<25
µmol/mmolCr)

Patient 1

Small peak

Patient 2

131

Plasma
cystine
(23–49
µmol/L)

Serum uric
acid (130–
330 µmol/L)

Xanthine
hypoxanthine

80–400 mg/L

5

162

Normal

Agenesis of
corpus
callosum

0

1347-1350delTTGT

40 mg/L

4

187

Normal

Giant
cisterna
magna

Not done

1347-1350delTTGT

Urine sulfite
(not detected)
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Table 3. Genomic findings
Disease

Gene

Inheritance

HGVS cDNA

NM

Mutation

Protein

Sulfite oxidase
deficiency

SUOX Autosomal NC_000012.11:
NM_000456.2:
c.1521_1524delTTGT p.C508Rfs∗ 109
recessive
g.56398694_56398697delTTGT
c.1521_1524delTTGT

Variant
interpretation
Pathogenic

to an encephalopathic state. A significant proportion of patients develop complete or partial
ectopia lentis. Although milder cases have been described, in the classic presentation, death
occurs at an early age, and none of the treatments tested to date improved the clinical outcome (Johnson and Duran 2001). The preliminary diagnosis is made by elevated urinary sulfites, increased excretion of thiosulfate, increase in S-sulfocysteine, and normal serum uric
acid, xanthine, and hypoxanthine. Confirmatory diagnosis is made by measuring sulfite oxidase activity in liver or fibroblasts or identifying a disease-causing mutation in SUOX. To
date there have been 21 missense/nonsense mutations, seven small deletions, and one
small insertion in SUOX reported in individuals with isolated sulfite oxidase deficiency
(HGMD). The mutation identified here resulted in severe sulfite oxidase deficiency with early
onset and severe clinical manifestations.

SUMMARY
It is important to consider isolated sulfite oxidase deficiency/molybdenum cofactor deficiency particularly when dealing with severe seizures and developmental delay in infancy.
Screening of fresh urine for sulfites is a simple test but has false positives and false negatives.
Urine for thiosulfate can be falsely positive with sulfur containing antibiotics and some anticonvulsants. Urine screening for S-sulfocysteine is more reliable. Uric acid is normal in isolated sulfite oxidase deficiency as compared to molybdenum cofactor deficiency, in which it is
usually low. Cranial MRI and EEG are usually abnormal although not diagnostic. The mutation described here of a 4-bp deletion 1347–1350delTTGT in SUOX, in two unrelated
Indigenous patients predicts a premature termination of the sulfite oxidase protein.
Carrier screening for this deletion mutation will be offered to the patients’ extended families.
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